Financial data for 2025 indicates that B BRAUN reported €9.396 billion in sales, €1.220 billion EBITDA, and €461 million profit before taxes.[2]

Origins in 1839

The history of B BRAUN dates to June 23, 1839, when Julius Wilhelm Braun, aged 31, purchased the Rose Pharmacy in Melsungen for 14,000 thalers. The original business operated primarily as a pharmacy, which Braun subsequently expanded with a mail-order service for herbal remedies. This small pharmaceutical operation laid the foundation for what would become the B BRAUN Group.[1]

The company’s development is distinguished by its retention of family influence across six generations while transforming from a local pharmacy into a multinational healthcare corporation.[2]

Early Pharmaceutical and Medical Product Development

In subsequent generations, the Braun family transitioned beyond conventional pharmacy operations into manufacturing. A significant early milestone was the production of catgut, a sterile, absorbable surgical suture material. Records indicate that B BRAUN first produced sterile absorbable catgut in 1908, marking a shift toward large-scale medical product manufacturing.[2] Other early innovations included various pharmaceutical products, wound-care items, and medical materials.

Internationalization and Infusion Products (1920s–1940s)

B BRAUN established its first foreign production facility in Milan, Italy, in 1925, initiating its international expansion.[2] In 1930, the company developed Sterofundin, a balanced electrolyte solution that served as the precursor for future generations of B BRAUN electrolyte solutions.[2] During this period, the company also continued to advance its surgical sutures and other medical treatment products.

The historical trajectory of B BRAUN is closely linked to innovations in infusion therapy and vascular access.

Perfusor

In 1951, B BRAUN introduced the Perfusor, an early mechanical syringe pump designed for continuous infusion. This device became a foundational element of the company’s infusion technology portfolio.[2]

Plastic Infusion Containers

In 1956, B BRAUN began manufacturing infusion solution containers from plastic. These containers offered distinct advantages over fragile glass alternatives and facilitated the development of modern single-use infusion systems.[2]

Braunüle

In 1962, the company launched the Braunüle, described as its first one-piece plastic cannula for continuous infusion. This innovation was particularly significant as intravenous access is fundamental to modern hospital medicine.[2]

Infusomat

Expanding its infusion pump technology, B BRAUN introduced the Infusomat in 1971, which the company describes as its first volumetric infusion pump.[1] These developments cemented B BRAUN’s status as a major entity in infusion therapy, a sector that remains central to its business operations.

A significant component of B BRAUN is Aesculap, its surgical and orthopedic division. The origins of Aesculap predate its acquisition by B BRAUN; Gottfried Jetter began manufacturing surgical instruments in Tuttlingen, Germany, in 1867. The company subsequently developed a range of surgical instruments, orthopedic products, and medical technologies.

B BRAUN acquired a majority interest in Aesculap AG in 1976, and Aesculap was fully incorporated into the B BRAUN Group as a division in 1998.[2] Today, Aesculap is one of three principal divisions, covering:

• Surgical instruments
• Surgical technologies
• Orthopedic implants
• Neurosurgery
• Spine surgery
• Minimally invasive surgery
• Surgical visualization
• Operating-room solutions

Aesculap provides comprehensive solutions across surgical and operative processes, ranging from instruments and technologies to implants and related services.[2]

B BRAUN is a key provider in extracorporeal blood treatment, specifically dialysis. Following the advent of clinical dialysis in the 1950s, the company began supplying relevant technologies. By the late 1960s, it had commenced manufacturing its own dialysis machines in cooperation with FRABA.[1]

The company later expanded its scope from equipment manufacturing to operating dialysis centers. Since 2008, the B. Braun Avitum business has operated as a global full-service provider for extracorporeal blood treatment, encompassing equipment, consumables, services, and renal care centers. The company currently operates more than 360 renal-care centers worldwide.[1]

Clinical nutrition constitutes another vital segment of the B BRAUN healthcare portfolio. The company offers solutions for patients unable to obtain adequate nutrition through normal dietary intake, including those with critical or chronic illnesses. Activities in this domain include:

• Parenteral nutrition
• Enteral nutrition
• Nutritional solutions
• Infusion technology
• Nutrition-related clinical systems

B BRAUN approaches nutrition as an integrated therapeutic system rather than merely a pharmaceutical or food product category.[2]

B BRAUN possesses a long-standing history in wound closure. Following its early production of catgut, the company developed additional surgical suture materials, eventually introducing synthetic materials and tissue adhesives. Key products in this portfolio include:

• Synthofil A
• Supramid
• Histoacryl
• Monosyn

These products address various approaches to closing and managing surgical or traumatic wounds, including both sutures and tissue adhesives.[2]

B BRAUN organizes its healthcare solutions into three primary divisions:

Hospital Care

Hospital Care focuses on technologies utilized in hospitals and clinical environments. Key areas include:

• Infusion therapy
• IV access
• Infusion pumps
• Injection and infusion products
• Clinical nutrition
• Pharmaceutical products
• Infection prevention
• Medication management

This division is associated with many of B BRAUN’s most recognized technologies, including infusion pumps and vascular access products.[2]

Aesculap

Aesculap serves as the surgical and orthopedic division. Its portfolio comprises:

• Surgical instruments
• Surgical systems
• Orthopedic implants
• Neurosurgical technologies
• Spine products
• Minimally invasive surgery
• Operating-room technologies

Rooted historically in Tuttlingen, Aesculap represents a significant link to Germany’s traditional surgical instrument industry.[2]

Avitum

Avitum concentrates primarily on extracorporeal blood treatment and renal care. Its activities include:

• Hemodialysis
• Dialysis machines
• Dialysis consumables
• Extracorporeal blood-treatment systems
• Renal-care centers
• Related services

The integration of equipment, consumables, and healthcare services distinguishes Avitum from a pure device-manufacturing business.[2]

B BRAUN differentiates itself from manufacturers of individual medical devices through a strategy emphasizing integrated healthcare solutions. The company combines medical devices, pharmaceuticals, consumables, software, services, and clinical expertise. For instance, a modern B BRAUN solution may integrate an infusion pump with administration sets, IV access products, medication management technology, software, and associated services, rather than supplying the pump alone.

These connected solutions aim to enhance patient safety, resource efficiency, workflow reliability, and cost effectiveness.[2] This approach is reflected in the corporate positioning: “True partner. Smart solutions. Set standards.”[2]

Although originating in Melsungen, Germany, B BRAUN is now a truly international entity. Corporate information indicates the company maintains more than 300 subsidiaries in 64 countries with approximately 5,000 healthcare products in its portfolio.[2] Operations span manufacturing, research and development, sales, distribution, healthcare services, and training across Europe, North and South America, Asia-Pacific, the Middle East, and Africa.

B BRAUN has maintained a presence in the Philippines for more than three decades. The Philippine organization supplies medical products and healthcare solutions covering:

• Sutures
• Infusion solutions and devices
• Disposable syringes
• Surgical instruments
• Hemodialysis machines and consumables
• Clinical nutrition
• Wound care
• Stoma care
• Diabetes care

B BRAUN Philippines emphasizes customer relationships and after-sales service as integral components of its local business operations.[1]

Innovation is central to the identity of B BRAUN. In 2025, the company invested approximately €584 million in research and development, representing an 11% increase compared to 2024 and accounting for more than 6% of revenue.[2]

The current innovation strategy prioritizes digitally connected healthcare. Rather than treating physical devices, digital technologies, and services as separate entities, B BRAUN develops integrated systems connecting medical devices, software, data, consumables, clinical workflows, and healthcare services. This integration is particularly relevant in infusion therapy, medication management, surgery, and dialysis.[2]

Fiscal year 2025 figures demonstrate the scale of B BRAUN’s operations:

Sales increased by 2.8% in reported currency, with 5.1% growth at constant exchange rates.[2] During the year, the company invested more than €800 million in its global production network and new technologies.[2]

A defining characteristic of B BRAUN is its status as a family-owned company. Despite significant growth, it has maintained a long-term ownership structure rather than becoming a publicly traded conglomerate. B BRAUN describes itself as an autonomous, family-run enterprise guided by entrepreneurship, innovation, responsibility, and long-term thinking.[2]

The company also emphasizes “Sharing Expertise”, a philosophy positing that medical innovation arises through cooperation among healthcare professionals, customers, researchers, engineers, and the company itself.

B BRAUN has established a comprehensive corporate responsibility program with initiatives dating back decades:

• A company pension fund was established in 1919.
• A company health insurance program followed in 1923.
• An employee relief fund was established in 1929.
• The B. Braun Foundation was founded in 1966 to support medical and nursing education.
• Environmental protection activities were formally instituted in 1989.
• A global Corporate Social Responsibility concept was introduced in 2008.
• A formal Code of Conduct was adopted in 2012.
• The first Sustainability Report was published in 2015.[2]

Sustainability is now integrated into the corporate strategy, encompassing economic, environmental, and social responsibilities.[2]

The importance of B BRAUN lies in the breadth of its healthcare ecosystem rather than a single product. Hospitals may encounter B BRAUN products across multiple stages of the patient journey: IV access → infusion → medication delivery → clinical nutrition → surgery → wound closure → dialysis/renal care. This extensive presence allows the company to operate across various clinical treatment stages.

Key strengths include:

• Long history: Over 185 years of development.
• Medical specialization: Focus on healthcare rather than consumer markets.
• Broad portfolio: Approximately 5,000 healthcare products.
• Global reach: Operations in more than 60 countries.
• Integrated solutions: Combination of products, software, and services.
• Strong R&D: Annual investment in the hundreds of millions of euros.
• Family ownership: Long-term corporate orientation.
• Clinical expertise: Close relationships with hospitals and healthcare professionals.[1]

[2]

1. B. Braun: Company History
2. Facts & Figures – B. Braun